目的 系統(tǒng)評(píng)價(jià)表柔比星（EPI）對(duì)比絲裂霉素（MMC）行膀胱灌注治療非肌層浸潤(rùn)性膀胱癌（NMIBC）的療效和安全性。方法 計(jì)算機(jī)檢索PubMed、Cochrane Library、Ovid平臺(tái)生物醫(yī)學(xué)數(shù)據(jù)庫(kù)（OVID）、SpringerLink、中國(guó)期刊全文數(shù)據(jù)庫(kù)（CNKI）、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)（CBM）、維普生物醫(yī)學(xué)數(shù)據(jù)庫(kù)（VIP）及萬(wàn)方數(shù)據(jù)庫(kù)中2000年1月1日—2023年2月1日發(fā)表的EPI（試驗(yàn)組）與MMC（對(duì)照組）治療術(shù)后NMIBC的臨床隨機(jī)對(duì)照試驗(yàn)（RCT），利用RevMan 5.3軟件進(jìn)行Meta分析。結(jié)果 共納入14項(xiàng)RCTs，1 103例患者，其中試驗(yàn)組553例、對(duì)照組550例。試驗(yàn)組術(shù)后腫瘤復(fù)發(fā)率［OR＝0.52，95% CI（0.38，0.71），P<0.000 1］、膀胱刺激征發(fā)生率［OR＝0.51，95% CI（0.32，0.81），P＝0.004］、血尿發(fā)生率［OR＝0.47，95% CI（0.28，0.78），P＝0.004］均顯著低于對(duì)照組，但是兩種藥物行術(shù)后膀胱灌注的其他不良反應(yīng)（肝腎損害、皮疹、惡心嘔吐、尿道狹窄）發(fā)生率比較，差異無(wú)統(tǒng)計(jì)學(xué)意義［OR＝0.67，95% CI（0.36，1.27），P＝0.22］。結(jié)論 使用EPI行膀胱灌注治療NMIBC患者的臨床療效略優(yōu)于MMC，但是仍需謹(jǐn)慎對(duì)待本次研究結(jié)果。

Objective To systematically evaluate the efficacy and safety of epirubicin (EPI) and mitomycin C (MMC) intravesical instillation in the treatment of non muscle invasive bladder cancer (NMIBC). Methods This research searched PubMed, the Cochrane Library, Ovid platform biomedical database (OVID), SpringerLink, CBM, CNKI, VIP and Wanfang databases for randomized controlled trials (RCTs) of EPI (treatment group) and MMC (controll group) for the treatment of postoperative NMIBC published from January 1, 2000 to February 1, 2023. Meta-analysis was performed using RevMan 5.3 software. Results A total of 14 RCTs with 1 103 patients were included, including 553 in treatment group and 550 in controll group. The rates of recurrence[OR=0.52, 95%CI (0.38, 0.71), P < 0.000 1], bladder irritation sign[OR=0.51, 95%CI (0.32, 0.81), P＝0.004], and hematuria[OR=0.47, 95%CI (0.28, 0.78), P＝0.004] after bladder instillation with EPI were significantly lower than those treated with MMC instillation. However, there was no significant difference in the incidence of other adverse effects (hepatic and renal impairment, rash, nausea and vomiting, and urethral stricture) related to postoperative bladder perfusion between the two drugs[OR=0.67, 95%CI (0.36, 1.27), P＝0.22]. Conclusions Intravesical instillation with EPI showed slightly better clinical outcomes than MMC in patients with NMIBC, but the results of this study still need to be taken with caution.

R983，R979.1

河南省重點(diǎn)研發(fā)與推廣科技攻關(guān)專項(xiàng)（182102310059）；河南省高等學(xué)校重點(diǎn)科研項(xiàng)目（21A320015）；新鄉(xiāng)市科技攻關(guān)項(xiàng)目（GG2020032）；2020年度新鄉(xiāng)醫(yī)學(xué)院第一附屬醫(yī)院青年培育基金（QN-2020-A05）